Patient Input Submissions
When a new drug for psoriasis or psoriatic arthritis comes to patients in Canada, it must be reviewed in the context of other drugs available for these diseases if the manufacturer wants it to be listed on a public drug formulary. The Quebec government has its own health technology assessment (HTA), done by the Institut national d’excellence en santé et en services sociaux (INESSS). All other government drug plans in Canada refer to the HTA done by Canada’s Drug Agency (CDA-AMC).
As part of these processes, patients are invited to share their experiences living with the disease, how helpful they find existing treatments, their treatment goals, and their experience with the new drug (if they have tried it) or their expectations of it (if they have not). Some provinces (BC, Ontario) have their own HTA processes that call for patient and caregiver input.
2026
Coming soon